Home > Insider Trading > Filing (0001181431-10-017475)

Filing Details

Accession Number:: 0001181431-10-017475
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2010-03-19 13:00:00
Reporting Period:: 2010-03-19

Filing Date:: 2010-03-19
Accepted Time:: 2010-03-19 17:19:45
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1062822	Lexicon Pharmaceuticals Inc.	LXRX	Pharmaceutical Preparations (2834)	760474169

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1053890	Raymond Debbane	C/O The Invus Group, Llc 750 Lexington Avenue, 30Th Floor New York NY 10022	No	No	Yes	No
1340098	Ulys, Llc	750 Lexington Avenue 30Th Floor New York NY 10022	No	No	Yes	No
1378005	Invus, Cv	Marten Meesweg 25 Rotterdam 3068 Av P7	No	No	Yes	No
1404553	Invus Advisors, L.l.c.	750 Lexington Avenue 30Th Floor New York NY 10022	No	No	Yes	No
1404570	Invus, L.p.	750 Lexington Avenue 30Th Floor New York NY 10022	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2010-03-19	59,296,749	$1.15	130,137,040	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2010-03-19	5,190,848	$1.15	135,327,888	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2010-03-19	29,021,739	$1.15	29,021,739	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2010-03-19	760,870	$1.15	29,782,609	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Footnotes

On March 19, 2010, Invus, L.P. agreed to purchase 59,296,749 shares of common stock of Lexicon Pharmaceuticals, Inc. (the "Issuer") from the Issuer. The purchase closed on March 19, 2010.
131,346,780 of the reported shares are owned directly by Invus, L.P. and 3,891,108 of the reported shares are owned directly by Invus Public Equities, L.P. and subject to a voting agreement pursuant to which Invus Public Equities, L.P. agreed to vote its shares of common stock of the Issuer at the sole direction of Invus, L.P. Invus Advisors, L.L.C. is the general partner of Invus, L.P. Ulys, L.L.C. is the managing member of Invus Advisors, L.L.C. Raymond Debbane is the sole member of Ulys, L.L.C. Accordingly, each of Invus Advisors, L.L.C, Ulys, L.L.C. and Raymond Debbane may be deemed to be indirect beneficial owners of the reported securities. Each of Invus Advisors, L.L.C., Ulys, L.L.C and Raymond Debbane disclaims beneficial ownership of such securities, except to the extent of its or his pecuniary interest therein.
On March 19, 2010, Invus, L.P. agreed to purchase 5,190,848 shares of common stock of the Issuer from the Issuer. The purchase closed on March 19, 2010.
On March 19, 2010, Invus C.V. agreed to purchase 29,021,739 shares of common stock from the underwriters in a public offering of common stock of the Issuer. The purchase closed on March 19, 2010.
The reported shares are owned directly by Invus C.V. Ulys, L.L.C. is the general partner of Invus C.V. Raymond Debbane is the sole member of Ulys, L.L.C. Accordingly, each of Ulys, L.L.C. and Raymond Debbane may be deemed to be indirect beneficial owners of the reported securities. Each of Ulys, L.L.C and Raymond Debbane disclaims beneficial ownership of such securities, except to the extent of its or his pecuniary interest therein.
On March 19, 2010, Invus C.V. agreed to purchase 760,870 shares of common stock of the Issuer from the Issuer. The purchase closed on March 19, 2010.